“First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience”. 2026. Mediterranean Journal of Hematology and Infectious Diseases 18 (1): e2026066. https://doi.org/10.4084/MJHID.2026.066.